Seguimiento bioquímico y dosis de medicamentos de EIM del metabolismo intermedio

  • Sara Guillén López Instituto Nacional de Pediatría
  • Lizbeth López-Mejía Instituto Nacional de Pediatría
  • Rosa Itzel Carrillo-Nieto Instituto Nacional de Pediatría
  • Leticia Belmont Martínez Instituto Nacional de Pediatría
  • Isabel Ibarra González Instituto Nacional de Pediatría
  • Cynthia Fernández-Lainez Instituto Nacional de Pediatría
  • Marcela Vela-Amieva Instituto Nacional de Pediatría


Los errores innatos del metabolismo intermedio (EIMi) son un grupo heterogéneo de enfermedades monogénicas pertenecientes al grupo de las enfermedades raras (ER), que afectan vías metabólicas de la síntesis o catabolismo de los hidratos de carbono, aminoácidos o lípidos.1 Estas enfermedades conllevan anormalidades bioquímicas que pueden cuantificarse en diferentes fluidos biológicos, lo que permite su diagnóstico.


Biografía del autor/a

Sara Guillén López, Instituto Nacional de Pediatría
Investigador en Ciencias Médicas tipo B en Laboratorio de Errores Innatos del Metabolismo y Tamiz


Referencias bibliográficas:

Jeanmonod R, Asuka E, Jeanmonod D. Inborn Errors Of Metabolism. [Internet] Treasure Island (FL): Stat Pearls Publishing 2022 Jan [Updated 2022 July 18]. Accessed 2022 August 23. Disponible en:

Waterval WA, Scheijen J, Ortmans-Ploemen M, Habets-van der Poel C, Bierau J. Quantitative UPLC-MS/MS analysis of underivatised amino acids in body fluids is a reliable tool for the diagnosis and follow-up of patients with inborn errors of metabolism. Clin Chim Acta. 2009; 407 (1-2): 36-42.

Bick D, Bick SL, Dimmock DP, Fowler TA, Caulfield MJ, Scott RH. An online compendium of treatable genetic disorders. Am J Med Genet C Semin Med Genet. 2021;187(1):48-54.

El-Hattab AW. Inborn errors of metabolism. Clin Perinatol. 2015; 42 (2): 413-39.

Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess. 2004;8(12): iii, 1-121.

Gambello MJ, Li H. Current strategies for the treatment of inborn errors of metabolism. J Genet Genomics. 2018;45(2):61-70.

Agana M, Frueh J, Kamboj M, Patel DR, Kanungo S. Common metabolic disorder (inborn errors of metabolism) concerns in primary care practice. Ann Transl Med. 2018; 6(24): 469.

Laurie E. Bernstein, Fran Rohr, Sandy van Calcar. Nutrition Management of Inherited Metabolic Diseases. Second Edition. USA: Springer; 2022. 415 p.

Kölker S, Garbade S, Greenberg CR, Leonard JV, Saudubray JM, Ribes A, et al. Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr Res. 2006; 59 (6): 840-847.

Boy N, Mühlhausen C, Maier EM, Heringer J, Assmann B, Burgard P, et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. J Inherit Metab Dis. 2017; 40 (1):75-101.

Frazier DM, Allgeier C, Homer C, Marriage BJ, Ogata B, Rohr F, et al. Nutrition management guideline for maple syrup urine disease: an evidence-and consensus-based approach. Mol Genet Metab. 2014;112(3):210-7.

Javadzadeh A, Gharabaghi D. Gyrate atrophy of the choroid and retina with hyper-ornithinemia responsive to vitamin B6: a case report. J Med Case Rep. 2007;1: 27.

Cui X, Jauregui R, Park KS, Tsang SH. Multimodal characterization of a novel mutation causing vitamin B6-responsive gyrate atrophy. Ophthalmic Genet. 2018; 39(4):512-516.

Tanzer F, Firat M, Alagoz M, Erdogan H. Gyrate atrophy of the choroid and retina with hyperornithinemia, cystinuria and lysinuria responsive to vitamin B6. BMJ Case Rep. 2011; 2011: bcr0720103200.

Baumgartner MR, Hörster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014; 9:130.

Huemer M, Diodato D, Schwahn B, Schiff M, Bandeira A, Benoist JF, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017;40(1):21-48.

Wolf B. Biotinidase Deficiency. [Internet]. Seattle (WA): University of Washington, Seattle. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews®; 1993-2022. 2000 Mar 24 [Updated 2016 Jun 9] Accessed 2022 June 26. Disponible en:

Zschocke J, Hoffmann GF. Vademecum metabolicum Diagnosis and treatment of inherited disorders. 5th edition. Germany. Thieme; 2020 .214 p.

Sacharow SJ, Picker JD, Levy HL. Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency. [Internet] Seattle (WA): University of Washington, Seattle. In: Adam MP, Mirzaa GM, Pagon RA, et al, editors. GeneReviews® 2004 Jan 15 [Updated 2017 May 18]; 1993-2022. Accessed 2022 March 13. Disponible en:

Li Q, Yang C, Feng L, Zhao Y, Su Y, Liu H, et al. Glutaric Acidemia, Pathogenesis and Nutritional Therapy. Front Nutr. 2021; 8: 704984.

Longo N, Dimmock D, Levy H, Viau K, Bausell H, Bilder DA, et al. Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria. Genet Med. 2019;21(8):1851-1867.

Grisch-Chan HM, Schwank G, Harding CO, Thöny B. State of the art 2019 on gene therapy for phenylketonuria, Human Gene Therapy. 2019;30 (10): 1274-1283.

Thomas JA, Hove J, Baker PR. Inborn Errors of Metabolism. [Internet] USA: En: Hay, Jr. WW, Levin MJ, Deterding RR, Abzug MJ. eds. Current Diagnosis & Treatment: Pediatrics 24 e. McGraw Hill; 2018. Accessed September 07, 2022. Disponible en:

van Wegberg AMJ, MacDonald A, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162.

Pharmacoeconomic Review Report: Sapropterin dihydrochloride (Kuvan) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep. Accessed 2022 august 7. Available from:

van Ginkel WG, Rodenburg IL, Harding CO, Hollak CEM, Heiner-Fokkema MR, van Spronsen FJ. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1. Paediatr Drugs. 2019; 21(6): 413-426.

van Ginkel WG, van Reemst HE, Kienstra NS, Daly A, Rodenburg IL, MacDonald A, et al. The Effect of Various Doses of Phenylalanine Supplementation on Blood Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients. Nutrients. 2019;11(11): 2816.

SERN Southeast regional genetic network management guidelines portal. [Internet] USA. Southeast regional genetics network/Genetic metabolic Dietitians International. First Edition 2017. (Accessed 2022 July 9) Disponible en :

Morris A, Kozich V, Santra S, Andria G, Ben-Omran TIM, Chakrapani AB, et al. Guidelines for the diagnosis and management of cystathione beta-synthase deficiency. J Inherit Metab Dis. 2017; 40 (1) :49-74.

Matsumoto S, Häberle J, Kido J, Mitsubuchi H, Endo F, Nakamura K. Urea cycle disorders-update. J Hum Genet. 2019; 64(9): 833-847.

Häberle J, Chakrapani A, Ah Mew N, Longo N. Hyperammonaemia in classic organic acidaemias: a review of the literature and two case histories. Orphanet J Rare Dis. 2018;13(1):219.

Forny P, Hörster F, Ballhausen D, Chakrapani A, Chapman KA, Dionisi-Vici C, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision. J Inherit Metab Dis. 2021;44(3):566-592.

Kim ES, Keam, SJ. Triheptanoin in the management of long-chain fatty acid oxidation disorders: a profile of its use. Drugs Ther Perspect. 2021; 37, 187–193.

Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2): 188-200.

Chinsky JM, Singh R, Ficicioglu C, van Karnebeek CDM, Grompe M, Mitchell G, et al. Diagnosis and treatment of tyrosine type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017;19 (2).

Strauss KA, Puffenberg EG, Morton DH. Maple syrup urine disease. [Internet] Seattle (WA): University of Washington, Seattle. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJK, Stephens K, et al. Editors. Genereviews; 2006 Jan 30 (updated 2020 Apr 23) Accessed 2022 July 6. Disponible en:

Isolvaleric Acidemia: Quick Reference Guide. [Internet]. European Registry and network for intoxication type metabolic diseases (E-IMD). Consensus Care Protocols and information Brochures. Junes 2014 (Accessed 2022 July 19) Disponible en:

Cómo citar
Guillén López, S., López-Mejía, L., Carrillo-Nieto, R., Belmont Martínez, L., Ibarra González, I., Fernández-Lainez, C., & Vela-Amieva, M. (2023). Seguimiento bioquímico y dosis de medicamentos de EIM del metabolismo intermedio. Acta Pediátrica De México, 44(1), 75-82.
Criterios pediátricos